BioSpace News Archive

Curis, Inc. today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024 , at 8:00 a.m. ET.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, published its Annual Report 2023 and provided a corporate update.

Poolbeg Pharma announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline for the treatment of oral ulcers in patient’s suffering from Behçet’s Disease.

Bayer and the German-based life science company, Evotec, announced that they have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases.

BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany.

MannKind Corporation announced that it will proceed with a first-in-human Phase 1 study of nintedanib DPI for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis.

Caris Life Sciences® and COTA, Inc. announced a collaboration to expand their multi-modal data offerings to support and accelerate biopharmaceutical drug development and patient care.

Zomedica Corp., a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, May 9th, 2024, at 4:30 p.m. ET to discuss the Company’s operational and financial highlights for its first quarter ended March 31, 2024.

NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon.

Replay and The University of Texas MD Anderson Cancer Center, announced that the Food & Drug Administration has issued a ‘safe to proceed’ for the Investigational New Drug application for PRAME TCR/IL-15 NK, an engineered T-Cell Receptor Natural Killer cell therapy for relapsed/refractory myeloid malignancies.